DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Earnings for DiaSorin S.p.A. (DIA.MI)
Earnings in 2023 (TTM): $212.26 M
According to DiaSorin S.p.A.'s latest financial reports the company's current earnings (TTM) are $212.26 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of DiaSorin S.p.A.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $212.26 M | $168.63 M |
| 2022 | $343.84 M | $254.14 M |
| 2021 | $421.26 M | $328.04 M |
| 2020 | $339.02 M | $261.48 M |
| 2019 | $228.16 M | $185.38 M |
| 2018 | $215.59 M | $166.81 M |
| 2017 | $188.52 M | $147.56 M |
| 2016 | $177.43 M | $118.55 M |
| 2015 | $158.34 M | $105.93 M |
| 2014 | $135.16 M | $88.69 M |
| 2013 | $136.44 M | $87.59 M |
| 2012 | $144.95 M | $92.19 M |
| 2011 | $166.95 M | $105.08 M |
| 2010 | $152.89 M | $95.38 M |
| 2009 | $108.38 M | $73.89 M |
| 2008 | $63.18 M | $39.52 M |
| 2007 | $45.16 M | $26.6 M |
| 2006 | $38.27 M | $23.52 M |
| 2005 | $14.59 M | $4.93 M |
| 2004 | $7.47 M | $3.82 M |
| 2003 | $3.09 M | $917.77 K |